Vickers to dispose of medical division:
This article was originally published in Clinica
Executive Summary
Vickers is to dispose of its entire medical division. The company says that "expressions of interest" from 15 bidders had been received for all or part of the group's medical interests. The sale could realise around £100 million ($159 million). Instrumentarium, the Finnish device manufacturer, bought Datex-Engstrom from Vickers earlier this month (see Clinica No 772, p 11).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.